Martin Stumpe, PhD, Chief Data & Artificial Intelligence Officer at Danaher, examines the factors affecting AI’s impact on drug discovery. The artificial intelligence (AI) boom in life sciences has sparked a rush of new technologies to design molecules fit for purpose. The potential is enormous, with promised benefits for both… Read More
Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. The summit sees experts and thought leaders… Read More
Dr Isaac Bentwich, Founder and CEO of Quris-AI examines the rise of alternative approaches to animal testing within drug discovery. Since the Federal Food, Drug, and Cosmetic Act of 1938, animal testing has served as the foundational model for biomedical research, offering scientists insights into disease mechanisms and drug safety. Read More
DDW Editor Reece Armstrong takes a look at some of the recent activity in cancer research and examines where the biggest opportunities are in oncology. In January this year, researchers from the University of Toronto (UoT) and Insilico Medicine published a paper detailing how quantum computing combined with generative AI… Read More
Rafael Carazo Salas, CEO and Founder of CellVoyant, explores AI’s potential for cell therapies. AI is already making big strides in biotechnology and healthcare, from its remarkable accuracy in detecting breast cancer from mammograms, to AI platforms such as DeepMind’s AlphaFold revolutionising protein structure prediction. One of the most promising areas… Read More
Diana Spencer speaks to Dr Muhunthan Thillai, CEO at Qureight, about the company’s AI-powered imaging analytics and the technology’s potential in lung diseases and beyond. DS: Can you provide some background to the company? MT: We are a core imaging laboratory using deep-learning and analytics to advance clinical trials and… Read More
AstraZeneca, Tempus AI and Pathos AI have entered a multi-year, strategic collaboration to build a multimodal foundation model in oncology. The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Upon completion, the model will be shared… Read More
Dr Kenneth Barr, Senior Vice President, Discovery Services at Syngene International, examines the reality of using AI in drug discovery and its relevance for CROs. In an industry where investments are huge, the time to market is over a decade, and success rates hover around 10%, technological advances that significantly… Read More
Kerstin Papenfuss, PhD, Director, Pharma, Deep Science Ventures, looks at the unmet need for fibrosis treatments and where drug discovery opportunities lay in terms of treatment and technology. Fibrosis is a complex pathological process characterised by excessive accumulation of extracellular matrix (ECM) components, particularly collagen, in response to chronic tissue… Read More
AI precision medicine company Sonrai Analytics has announced a strategic partnership with AI company Paige designed to improve access to AI capabilities for precision medicine research and development. The partnership will see the integration of Paige’s foundation models with Sonrai’s cloud-based data analytics and bioinformatics platform to make AI, machine… Read More
Potato, a technology company focused on building autonomous science agents, has announced $4.5 million in new funding, led by Draper Associates. The company says the funds will accelerate its mission to automate scientific research. Potato's AI agents orchestrate scientific workflows and use tools to execute computational and wet lab experiments. … Read More
Global health company M42 has announced a strategic investment and partnership with longevity biotech Juvenescence. The partnership will focus on identifying and developing a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases. The partnership will leverage M42’s expertise in genomics, biobanking and clinical… Read More
Lucy Sabin, Postdoctoral Researcher at the University of Sheffield’s Information School reports on a study that examines how computational and medicinal chemists in drug discovery feel about AI. Whilst they are positive about AI methods in the field, they‘re calling for more realistic expectations. A growing number of pharmaceutical companies… Read More
News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More
Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset. As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from the S:CORT dataset… Read More
The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, with the aim of harnessing artificial intelligence (AI) to revolutionise drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics… Read More
